Identification of the Autophosphorylation Sites of the Xenopus laevis Pim-1 Proto-oncogene-encoded Protein Kinase*

(Received for publication, December 17, 1996, and in revised form, February 14, 1997)

Chrystal K. Palaty Dagger §, Gabriel Kalmar , Georgia Tai Dagger , Stella Oh , Lawrence Amankawa par , Michael Affolter par , Ruedi Aebersold par and Steven L. Pelech Dagger **Dagger Dagger

From the Dagger  Department of Medicine, University of British Columbia, and ** Kinetek Pharmaceuticals, Inc., Vancouver, British Columbia V5Z 1A1, the  Institute of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia V5A 156, Canada, and the par  Department of Biotechnology, University of Washington, Seattle, Washington 98105

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

Pim-1 is an oncogene-encoded serine/threonine kinase expressed primarily in cells of the hematopoietic and germ line lineages. Previously identified only in mammals, pim-1 cDNA was cloned and sequenced from the African clawed frog Xenopus laevis. The coding region of Xenopus pim-1 encoded a protein of 324 residues, which exhibited 64% amino acid identity with the full-length human cognate. Xenopus Pim-1 was expressed in bacteria as a glutathione S-transferase (GST) fusion protein and in COS cells. Phosphoamino acid analysis revealed that recombinant Pim-1 autophosphorylated on serine and threonine and to a more limited extent on tyrosine. Electrospray ionization mass spectroscopy was undertaken to locate these phosphorylation sites, and the primary autophosphorylation site of GST-Pim-1 was identified as Ser-190 with Thr-205 and Ser-4 being minor sites. Ser-190, which immediately follows the high conserved Asp-Phe-Gly motif in catalytic subdomain VII, is also featured in more than 20 other protein kinases. To evaluate the importance of the Ser-190 site on the phosphotransferase activity of Pim-1, Ser-190 was mutated to either alanine or glutamic acid, and the constructs were expressed in bacteria as GST fusion proteins and in COS cells. These mutants confirmed that Ser-190 is a major autophosphorylation site of Pim-1 and indicated that phosphorylation of Pim-1 on the Ser-190 residue may serve to activate this kinase.


INTRODUCTION

Pim-1 (1) is a member of the small family of known proto-oncogene-encoded serine/threonine protein kinases. The pim-1 gene was first discovered as a preferential proviral integration site in murine leukemia virus-induced T and B cell leukemias (2, 3). Extensive transgenic studies have confirmed that pim-1 is an oncogene in mice (4-6), but the only evidence that Pim-1 contributes to human cancers is that the protein and mRNA levels for this kinase are elevated in some human tumors and cell lines (7-9).

Although the normal functions of Pim-1 have been obscure, its mRNA and protein expression patterns indicate that it is involved in hematopoietic signal transduction and development of male germ cells (1, 3, 7, 10, 11). Expression and stability of pim-1 mRNA and protein is tightly regulated at different levels, implying that the kinase is functionally potent (7, 9, 12-14). Pim-1 is induced by mitogens and growth factors, including GM-CSF,1 G-CSF, IL-2, IL-3, IL-5, IL-6, IL-7, concanavalin A, phorbol esters, interferon-gamma , Steel factor, and in response to T cell receptor cross-linking, and it may act as a cytoplasmic mediator in a signal transduction pathway (9, 12, 13, 15-18). Up-regulation of Pim-1 by signaling through the GM-CSF receptor family requires the presence of the GM-CSF receptor membrane proximal domain and may involve the JAK2 tyrosine kinase (19-24). STAT1 sites within the pim-1 gene support this hypothesis (18). During GM-CSF stimulation, Pim-1 is involved in a DNA synthetic pathway rather than an apoptotic inhibition pathway (24).

Relatively little is known concerning the post-translational regulation of Pim-1, even though it was identified as a protein kinase more than a decade ago (3). There has been no evidence (e.g. band shifts of Pim-1 during SDS-polyacrylamide gel electrophoresis) to support the phosphorylation of Pim-1 during signal transduction. Nor has the phosphotransferase activity of the kinase been shown to be affected by phosphorylation. Pim-1 can autophosphorylate, but the sites of autophosphorylation and the functional consequences of this event have not yet been determined (14, 25-27).

As Pim-1 phosphotransferase activity has not yet been shown to be regulated by upstream kinases, it is possible that an autophosphorylation event may modulate the activity of the kinase. One of the goals of this study was to identify the major autophosphorylation site in Pim-1 and to assess its role. Pim-1 has not yet been examined from non-mammalian systems, nor has it been purified to homogeneity. In this study, we have cloned Pim-1 from Xenopus laevis and characterized a purified glutathione S-transferase (GST) fusion form of this kinase that was expressed in Escherichia coli. The recombinant GST-Pim-1 was highly active and exhibited strong autophosphorylating activity in vitro. Immobilized metal affinity chromatography (IMAC) and high pressure liquid chromatography (HPLC)-electrospray ionization-mass spectrometry (ESI-MS) were employed to identify the main autophosphorylation site as Ser-190. Mutational analysis confirmed that Ser-190 was indeed the major site of autophosphorylation and indicated that phosphorylation of this residue serves to activate this kinase.


EXPERIMENTAL PROCEDURES

Materials

The Pim-1-CT and the Tel anti-Pim-1 antibodies were kind gifts from Dr. Michael Lilly (Seattle VA Hospital) and Drs. R. Amson and A. Telerman (CEPH, Paris, France), respectively. The anti-GST antibody was obtained from Molecular Probes, and the anti-phosphotyrosine monoclonal antibodies PY-20 and 4G10 were from Santa Cruz Biotechnology and Upstate Biotechnology Inc., respectively. The blotting grade affinity-purified goat anti-rabbit IgG (H+L) alkaline phosphatase conjugate was from Bio-Rad, and the electroimmunoassay grade affinity-purified goat anti-mouse IgG (H+L) alkaline phosphatase conjugate was obtained from Calbiochem. Pim-1 substrate peptide (AKRRRLSA) was produced on an Applied Biosystems 430A peptide synthesizer and purified in the laboratory of Dr. Ian Clark-Lewis (Biomedical Research Center, University of British Columbia). Phosphatase HPTPbeta was a kind gift from Ken Harder (Biomedical Research Center). The pGEX-2T vector was from Pharmacia Biotech Inc. The E. coli bacterial strain UT5600 as well as restriction enzymes BamHI and HindIII were from New England Biolabs. The isopropyl beta -D-thiogalactopyranoside was from Fisher. The cAMP-dependent protein kinase inhibitor peptide, soybean trypsin inhibitor, and other reagents were from Sigma. All oligonucleotides were synthesized on an Applied Biosystems 392 DNA synthesizer.

Cloning of X. laevis Pim-1

Stage VI immature oocytes were isolated from the ovaries of mature female X. laevis (28) and washed with 1 × Xenopus oocyte medium (29). Total RNA was isolated from these oocytes and used as a template to make cDNA (30). A Xenopus pim-1 probe was constructed using oligonucleotides based on the sequences of human and murine pim-1 sequences (31). Sense and antisense primers (5'-CTG ACC CGG GCT CGA GGC ICC IGG IAA (G/A)GA (G/A)AA (G/A)GA (G/A)CC-3' and 5'-CTG ACC CGG GCT CGA GAT (C/T)TC (C/T)TC (G/A)TC (G/A)TG TTC (G/A)AA IGG-3', respectively) were expected to yield a 669-base pair product. PCRs were carried out for 29 cycles with an initiation temperature of 94 °C for 35 s, annealing at 50 °C for 90 s, and elongation for 73 °C for 90 s. PCR products were subcloned into pBluescript, amplified, examined by restriction digest analysis, and the identity of the PCR clones was confirmed by sequencing, using a double template protocol as dictated by the Pharmacia kit. A Xenopus oocyte cDNA library was kindly supplied by Dr. Leonard Zon (Children's Hospital, Boston) and was screened with the amplified Xenopus PCR fragment by standard methods (30). Positive clones were amplified and sequenced using the standard dideoxy chain termination method (32). Sequence searches were performed with a software package developed by Dr. Allen Delaney (Biomedical Research Center).

Construction of Mutant Pim-1 Bacterial Expression Vectors Using PCR

The coding region of the X. laevis pim-1 was amplified from a cDNA clone by PCR using the pim-1 based oligonucleotides, 5'-CGA TCT TCT CTC TAA ATT CGG-3' and 5'-GAT CCA GAC TCT CGT TGC TTG A-3', which allowed directional, in-frame insertion into the pGEX-2T vector. To create the kinase-inactive (K69A) Pim-1 mutant, PCR was used with the 5' sense primer and the antisense primer K1, 5'-CTC CTT AGC TAC GTG  CAC AGC GAC CGG CTG-3' (corresponding to amino acids 64-74, with the lysine codon, TCC (nucleotides 205-207), changed to an alanine codon, GCG). To create Ser-190 mutants of Pim-1, sense primer PM1 (5'-CTG ATC GAT TTT GGC  GGG GCG CTA CTC-3') was used to make a serine to alanine mutant (S190A) and the sense primer PM2 (5'-CTG ATC GAT TTT GGC  GGG GCG CTA CTC-3') was used to make a serine to glutamic acid mutant (S190E) of Pim-1. Both sense primers were used with PM3 (5'-GAT CGA ATT CCA GAC TCT CGT TGC TTG A-3') to amplify a 415-base pair fragment that was used to replace the ClaI/EcoRI fragment of WT Xenopus pim-1. PCR products were purified, digested, and ligated into appropriate restriction sites of pGEX-2T. The ligations were used to transform DH5a high competence cells (Life Technologies, Inc.), and positive clones were selected on the basis of ampicillin resistance. All clones were sequenced to confirm that the mutations were as expected.

Production of GST Fusion Proteins

The pGEX-2T vectors containing Xenopus WT and mutant pim-1 inserts were used to produce GST-Pim-1 fusion protein. In brief, UT5600 E. coli (New England Biolabs) was transfected with the pim-1-containing pGEX-2T vectors and grown in 2 × YT medium (30) in the presence of 75 µg/ml ampicillin. The expression of the fusion protein was induced with 200 µM isopropyl beta -D-thiogalactopyranoside for 3 h. The bacterial were pelleted by centrifugation at 2,000 × g for 15 min, the pellet was washed in 25 ml of phosphate-buffered saline and resuspended in 10 ml of phosphate-buffered saline containing 1 mM EDTA, 0.1 mM EGTA, 0.2 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, and protease inhibitors (10 µg/ml) aprotinin, leupeptin, and soybean trypsin inhibitor. Lysozyme (200 µg/ml) and DNase (50 mg/ml) were added to each pellet, followed by incubation on ice for 30 min. The lysate was centrifuged (12,000 × g for 10 min at 4 °C), and the supernatant was removed and added to glutathione-agarose beads and mixed gently on a rotator at 4 °C for 30 min. The beads were then poured into a 1-cm-diameter column and washed with 10 volumes of STE buffer (50 mM Tris-HCl, pH 8.0, 4 mM EDTA, 150 mM NaCl, 0.1% Triton X-100), followed by 10 volumes of STEC buffer (50 mM Tris-HCl, pH 8.0, 200 mM NaCl, 6 mM CaCl2). The fusion protein was eluted from the beads with 10 mM glutathione in STEC buffer and immediately frozen at -70 °C.

Production of Anti-Pim-1 Antibodies

The affinity-purified rabbit polyclonal Pim-1 anti-peptide antibodies were prepared as described by Sanghera et al. (33) and are commercially available from Upstate Biotechnology Inc. Pim-1-III was based on the kinase subdomain III region of the human Pim-1 (amino acid residues 70-91). Pim-1-NT was patterned after the amino terminus of human Pim-1 (amino acid residues 1-37). Anti-Pim-1-XI was raised against a peptide modeled on the catalytic subdomain XI of xPim-1 (residues 275-292). Rabbit polyclonal antiserum was produced against the full-length GST-xPim-1 bacterial fusion protein eluted from the glutathione beads after concentration. Rabbits were first injected with 250 µg of GST-xPim-1 in incomplete Freund's adjuvant; 200 µg was used for the second and third injections, and 100 µg of the fusion protein was used for each successive injection. The rabbits were bled and the serum purified by protein G purification following the manufacturer's protocol (Pharmacia). The protein G-purified serum (1.5 ml) was incubated with rotation for 30 min at 4 °C with GST beads (500 µl) to remove any antibodies specific for GST. The beads were centrifuged and washed once with 500 µl of phosphate-buffered saline (4 °C), and the supernatants were combined, aliquoted, and frozen.

Creation of Pim-PEF1 Expression Vectors, Transfection, and COS Expression

The coding region of Xenopus WT pim-1 was amplified using PCR oligomutagenesis using oligonucleotides 5H6PM (5'-(P) ATG GAA GAG GAA GAG GAA GAG CTT CTC TCT AAA TTC GGA TCG - 3') and PM3' (5'-CAA AGC TTT ACA GAC TCT CGT TGC TTG AGC-3'), which added a 5' tag of six glutamic acid residues on the Pim-1 protein. The PCR fragment was subcloned into the SmaI site of the PEF1 expression, vector and then the Pim-PEF1 vectors were transformed into DH5a/P3 bacteria. Transformed bacteria were grown on plates containing both ampicillin (100 µg/ml) and tetracycline (10 µg/ml). Clones were selected for the presence of an insert by digestion with SalI, the orientation of the inserts was determined by BglII digestion, and the ends of the WT and the mutants were sequenced to confirm that the ligation was as expected.

Positive clones were transfected into the COS cells and grown 72 h before harvesting. Cells were homogenized in buffer containing 10 mM MES, pH 6.0, 50 mM beta -glycerophosphate, 2 mM MgCl2, 2 mM phenylmethylsulfonyl fluoride, 1 mM EGTA, 1 mM dithiothreitol, 100 µM Na3VO4, 0.5% Triton X-100, and 10 µg/ml each of leupeptin and aprotinin. The homogenates were sonicated then centrifuged at 12,000 × g to separate the supernatant and pellets, which were frozen immediately. Samples of the homogenates, supernatants, and pellets were analyzed by Western blotting.

Glutamic acid-tagged Pim-1 proteins were partially purified by fractionation on Resource Q column chromatography. COS extract (2 mg) was applied to a 2-ml Resource Q column and eluted with a 0-0.8 M NaCl gradient over 10 ml, in buffer containing 10 mM MOPS, pH 7.2, 25 mM beta -glycerophosphate, 2 mM EDTA, 5 mM EGTA, 2 mM Na3VO4. Fractions of 0.25 ml were collected and analyzed for the presence of Pim-1 by assays with Pim-1 substrate peptide and Western blotting.

In Vitro Autophosphorylation of Expressed GST-xPim-1

Phosphorylations were performed in a final volume of 50 µl, with 1-25 µg of GST-xPim-1 in 5 µl of STEC buffer, 250 µM [gamma -32P]ATP (6 × 103 cpm/pmol), 500 nM cAMP-dependent protein kinase inhibitor, and assay dilution buffer containing 10 mM MOPS, pH 7.2, 10 mM MgCl2, and 1.25 mM MnCl2. Preincubations were performed over ice, and the kinase reaction at 30 °C for 30 min was started with the inclusion of the ATP and terminated by the addition of 50 µl of 2 × SDS-sample buffer. The sample was boiled for 5 min and clarified by centrifugation and the supernatant electrophoresed on a 10% SDS-polyacrylamide gel. In some experiments, the gels were stained to ensure that the amount of protein loaded per lane was consistent. The gels were dried, and radioactive bands were cut from the gel and counted by scintillation counting. Stoichiometry of autophosphorylation was determined by measuring the mol of ATP incorporated per mol of GST-xPim-1. In other experiments, the GST-xPim-1 was transferred from the SDS-polyacrylamide gel onto polyvinylidene difluoride membrane for Western blotting and autoradiography.

Phosphorylation of Synthetic Peptide Substrate by Expressed xPim-1

The peptide (AKRRRLSA) was determined previously to be an optimal substrate for Pim-1.2 Pim-1 substrate peptide phosphorylations were performed in a final volume of 25 µl, with 1 mg/ml peptide, 0.5 µg of GST-xPim-1 in 5 µl of STEC buffer, 50 µM [gamma -32P]ATP (2,000 cpm/pmol), 1.5 mM MnCl2 or 25 mM MgCl2, 0.5 µM cAMP-dependent protein kinase inhibitor peptide, and assay dilution buffer. All preincubations were performed on ice, and the kinase reactions at 30 °C for 10 min were started with the addition of the ATP and terminated by application of 20 µl of the reaction mixture onto a 1.5-cm2 piece of Whatman P81 phosphocellulose paper. Filter papers were washed in phosphoric acid (1% v/v) and the radioactivity quantitated in an LKB Wallac 1410 scintillation counter.

Phosphoamino Acid Analysis and Tryptic Phosphopeptide Mapping of in Vitro Autophosphorylated xPim-1

32P-Labeled GST-xPim-1 (by autophosphorylation) on a polyvinylidene difluoride membrane was visualized by autoradiography, excised from membrane, and chopped into 0.5-mm2 pieces. For phosphoamino acid analysis, membrane-bound protein was digested in 300 µl of constant boiling HCl at 105 °C for 1.5 h. The acid was removed, and the membrane was washed briefly with dH2O to remove residual amino acids. Water and acid were removed by evaporation in a vacuum centrifuge, and amino acids were sequentially washed and vacuum dried. Amino acids were redissolved in water/acetic acid/pyridine buffer (94.5/5/0.5 v/v/v) containing 1 mg/ml each of phosphoserine, phosphothreonine, and phosphotyrosine standards. Phenol red (0.5% in buffer (w/v)) was spotted on the origin as a control. Approximately 2,000 cpm were spotted 2 cm from the bottom of a cellulose sheet (Kodak chromogram) and electrophoresed for 1.5 h at 750 volts until the phenol red spot had migrated 7-8 cm from the origin. The plate was air dried and sprayed with ninhydrin solution (0.25% in ethanol) and developed to visualize standards either by heating with a hairdryer or by baking in an oven at 90 °C for 5 min. X-ray film was exposed to the cellulose sheet for 18 h and subsequently developed.

The full-length radiolabeled xPim-1 fusion protein was detected by autoradiography and excised from the gel for tryptic two-dimensional phosphopeptide mapping (34). Phosphoamino acid analysis was performed on resolved phosphopeptides that were extracted from the cellulose plate with two washes of 200 µl of 20% acetonitrile (0.1% trifluoroacetic acid) and once with 200 µl of 60% acetonitrile, with sonication in a water bath sonicator for 5 min between extractions to break up the cellulose.

IMAC-HPLC-ESI-MS Analysis of xPim-1 Tryptic Peptides

Two samples of expressed GST-xPim-1 were prepared, with an estimated 4.2 mg of fusion protein bound to 5 mg of glutathione beads/sample. One sample was autophosphorylated in vitro with cold ATP, and the other was assumed to be autophosphorylated or phosphorylated in vivo. Both samples were washed extensively with thrombin buffer and digested with 10 µg of thrombin for 1 h at room temperature. After thrombinization, the slurries were poured into columns and the flow-through and eluate collected. The columns were washed with 2 volumes of thrombin buffer and the flow-through and eluate were concentrated in Centricon-10 tubes by sequential centrifugation and washes with 50 mM ammonium bicarbonate buffer. Once the volume of the Pim-1 was reduced to 100 µl, 10 µl of trypsin was added, and the sample was allowed to digest for 24 h at 37 °C, with constant agitation.

Following tryptic digestion of the GST-xPim-1, the resultant phosphopeptides were analyzed by IMAC-HPLC-ESI-MS. Micro-IMAC-HPLC-ESI-MS was performed using instrumentation and protocols as detailed elsewhere (35).

Samples were subjected to ESI-MS analysis on a PE Sciex (Thornhill, Ontario) APIIII triple quadruple mass spectrometer equipped with a pneumatically assisted ESI source (ion spray). The mass to charge ratio (m/z) was scanned repetitively over the range of 300-2,000. The output data from the mass spectrometer were analyzed with computer software provided with the machine. Mass spectra were displayed for observed peaks of ion detection events, and mass ranges from the data set could be extracted. Peptide masses were calculated based on computer matching of observed signals with the predicted m/z values for the various possible charge states of the same peptide and the theoretical fragmentation of the peptide sequence listing all possible fragments along with predicted charged mass values.


RESULTS

Cloning of Xenopus Pim-1

Degenerate oligonucleotides based on the human pim-1 sequence were successfully used to amplify part of the pim-1 coding region from X. laevis cDNA. This pim-1 PCR fragment was used as a probe to detect and identify the amphibian cognate from an Xenopus oocyte cDNA library. The full-length Xenopus pim-1 cDNA clones were approximately 2.7 kilobases in length, similar in size to that found in other species (25, 26, 31, 36). A 969-base pair open reading frame was included in the 1,348 nucleotides sequenced, which specified a 323-amino acid protein with a molecular mass of 36,970 daltons (Fig. 1).


Fig. 1. Protein sequence alignment of Pim-1 from Xenopus, mouse, rat, and human. Stars indicate identical amino acid residues, and dots indicate residues that are conserved among all four species. Roman numerals indicate conserved protein kinase subdomains. Residues that are highly conserved among all protein kinases are shown in bold type. Residues in xPim-1 which have been identified as phosphorylation sites are boxed.
[View Larger Version of this Image (63K GIF file)]


Xenopus Pim-1 (xPim-1) shares a high degree of amino acid sequence similarity with its mammalian counterparts (Fig. 1). The xPim-1 amino acid sequence has 86% overall homology and 65% overall identity with human Pim-1, with the regions of highest homology in the catalytic domain (71% identity). Although the xPim-1 NH2 terminus shares 49% identity with human Pim-1, the two proteins only exhibit 15% identity within their COOH termini, and the amphibian Pim-1 is eight amino acids longer.

Bacterially Expressed Pim-1 Autophosphorylates in Vitro

xPim-1 was expressed as a bacterial fusion protein. Analysis by Western blotting demonstrated that the expected 549-amino acid, 63.3-kDa fusion protein was produced (Fig. 2A). Of the seven different Pim-1 antibodies tested, those that were developed against xPim-1 amino acid sequences gave the strongest signals on Western blots. Bacterial expression of GST-xPim-1 yielded a relatively pure preparation with few degradation products as shown by Amido Black staining (Fig. 2B, lane 5), and the full-length fusion protein was the major species radiolabeled in an in vitro autophosphorylation reaction of GST-xPim-1 (Fig. 2B, lane 7). However, the stoichiometry of autophosphorylation of GST-xPim-1 was less than 0.01 mol/mol; as discussed later this reflected substantial phosphorylation of the GST-xPim-1 in E. coli prior to cell lysis. Only the full-length GST-xPim-1 was analyzed in detail because thrombin cleavage yielded poor recoveries of phosphotransferase activity (>3%) and xPim-1 protein (data not shown).


Fig. 2. Bacterial expression of recombinant GST-xPim-1. E. coli-expressed GST-xPim-1 purified by glutathione-agarose chromatography was subjected to SDS-polyacrylamide gel electrophoresis on a 10% polyacrylamide gel (0.75 µg/lane). Panel A, the gels were immunoblotted with the following antibodies: lane 1, anti-GST; lane 2, anti-GST-xPim-1; lane 3, anti-Pim-1-XI; lane 4, anti-Pim-1-NT; lane 5, anti-Pim-1-III; lane 6, anti-Pim-1 antibody from Dr. Telerman; lane 7, anti-Pim-1 antibody from Dr. Lilly; lane 8, anti-Pim-1 antibody from Cambridge Research Biochemicals; lane 9, 4G10 anti-phosphotyrosine antibody; lane 10, PY-20 anti-phosphotyrosine antibody. Panel B, bacterially expressed, purified, and autophosphorylated WT GST-xPim-1 (lanes 1, 3, 5, and 7) and a K69A kinase-inactive mutant of GST-xPim-1 (lanes 2, 4, 6, and 8) were Western blotted with anti-GST-xPim-1 antibody (lanes 1 and 2) and 4G10 anti-phosphotyrosine antibody (lanes 3 and 4). Amido Black staining of 2 µg of recombinant proteins is shown in lanes 5 and 6, and an autoradiogram of these lanes is presented in lanes 7 and 8. The migration positions of molecular mass marker proteins are indicated. Panel C, phosphoamino acid analysis of WT GST-xPim-1.
[View Larger Version of this Image (57K GIF file)]


Phosphoamino acid analysis revealed that GST-xPim-1 autophosphorylates primarily on serine and threonine residues and to a minor extent on tyrosine residues (Fig. 2C). In vitro autophosphorylation of GST-Pim-1 on tyrosine was also demonstrated by detection by anti-phosphotyrosine antibodies on a Western blot (Fig. 2, lanes 9 and 10). Likewise, we observed that human GST-Pim-1 also autophosphorylates on phosphotyrosine by phosphoamino acid analysis and Western blotting with anti-phosphotyrosine antibodies (data not shown). The autophosphorylation of Pim-1 on tyrosine was unexpected because the most recent studies have reported that the Pim-1 autophosphorylated strictly on serine and threonine residues (14, 26, 27, 37).

A kinase-inactive mutant of Xenopus GST-Pim-1 was created as a negative control to ensure that contaminating or copurifying proteins did not contribute to kinase activity. The kinase-inactive Pim-1 mutant was created by changing Lys-69, a residue required for ATP binding, to an alanine residue. The kinase-inactive Pim-1 mutant failed to immunoreact with anti-phosphotyrosine antibodies (Fig. 2B, lane 4). Furthermore, it was not radiolabeled in an autophosphorylation assay, even though a faintly radiolabeled 70-kDa protein was present in the kinase-inactive Pim-1 mutant preparation (Fig. 2B, lane 8); as this protein was also detected by the anti-GST-xPim-1 antibody, it was probably part of the original immunizing preparation. Although this 70-kDa protein possessed autokinase activity, it did not phosphorylate the kinase-inactive GST-Pim-1. This may be the product of the bacterial dnaK gene, a close homolog of the eukaryotic heat-shock protein family that increases in response to stress and may bind preferentially to abnormal (expressed) proteins along with other heat-shock proteins (grpE, La) enhancing susceptibility to cellular proteases (38-40).

Two-dimensional Phosphopeptide Analysis of xPim-1 Autophosphorylation Sites

Two-dimensional separation of tryptic phosphopeptides produced from in vitro autophosphorylated GST-xPim-1 yielded two strongly phosphorylated peptides (spots 1 and 2), as well as a number of moderate and weakly phosphorylated peptides (Fig. 3A). Each spot was numbered (Fig. 3B) for reference. The addition of increasing amounts of trypsin caused the relative strength of some spots to change, indicating that some of these peptides were the result of incomplete tryptic cleavage. None of the minor spots disappeared completely even when higher amounts of trypsin were used. Dephosphorylation of GST-xPim-1 with phosphatases prior in vitro autophosphorylation did not result in any significant changes in the relative intensities of the different spots.


Fig. 3. Two-dimensional tryptic phosphopeptide mapping of GST-xPim-1. Panel A, autoradiogram of a two-dimensional map of autophosphorylated and trypsinized GST-xPim-1. The origin is shown with a small circle, and the arrow indicates the direction of electrophoresis in the first dimension. Panel B, phosphoamino acid analysis was performed on the major phosphopeptides in panel A after their extraction from the cellulose matrix, and the results are summarized in this figure.
[View Larger Version of this Image (72K GIF file)]


After extraction from the TLC plate, peptides identified by two-dimensional phosphopeptide analysis were subject to phosphoamino acid analysis. The results of this experiment are summarized in Fig. 3B. Some samples did not yield enough radioactivity to warrant further analysis by IMAC-HPLC-ESI-MS.

Identification of Isolated Tryptic Phosphopeptides by IMAC-HPLC-ESI-MS

Phosphorylated peptides were selectively retained by the IMAC column and eluted from the matrix with sodium phosphate buffer and were subjected to subsequent analysis by HPLC-ESI-MS. A total ion chromatogram for sample 7 is shown in Fig. 4, which reveals the presence of two major charged species. Similar analyses were performed on the rest of the peptides. Although each sample should ideally contain only one peptide, additional peptides may be present because of comigration with the phosphopeptide of interest on the total ion chromatogram or may also be present because of noncovalent interaction with the phosphopeptide of interest. Peaks that corresponded to tryptic peptides of GST-Pim-1 were sequenced by the sequential cleavage of the NH2 terminus during MS. Samples not yielding interpretable results are not described.


Fig. 4. Representative total ion chromatogram of tryptic phosphopeptide 7. Two main peaks corresponding to the threonine-phosphorylated peptide are shown.
[View Larger Version of this Image (15K GIF file)]


Using IMAC-HPLC-ESI-MS, two definite sites of xPim-1 autophosphorylation were identified, and one additional autophosphorylation site was indicated. A tryptic peptide corresponding to amino acids 185-195 (LIDFGSGALLK), containing the phosphorylated residue Ser-190, was identified in sample 1 (Fig. 5A). The mass spectrum shows the singly charged species [M+H]+, the sodium adduct [M+Na]+, the doubly charged species [M+2H]2+, as well as the fragmentation products y7, y8, y9 and y10. A tryptic peptide corresponding to amino acids 196-206 (DTVYTDFDGTR) was identified in sample 7 (Fig. 5B). Although this peptide contained four potentially phosphorylatable residues, analysis indicated that Thr-205 was the phosphorylated residue.


Fig. 5. Mass spectra of tryptic phosphopeptides. Panel A, phosphopeptide 1, amino acids 185-195, LIDFGGALLK. Panel B, phosphopeptide 7, amino acids 196-206, DTVYTDFDGR. Phosphorylated amino acid residues are underlined.
[View Larger Version of this Image (22K GIF file)]


A third site of xPim-1 autophosphorylation was indicated as Ser-4, in a tryptic peptide corresponding to the last two residues of GST and the first 5 residues of Pim-1 (GSMLLSK) (data not shown). This sample also contained a peptide and peptide fragments corresponding to amino acids 56-60 of GST, PYYID. Although this second peptide was not phosphorylated, it may have been retained on the IMAC column by interaction with the other bound peptides.

An additional phosphorylated peptide was identified in the GST portion of the fusion protein. The mass data analysis of this pinpointed Thr-17 as being the phosphorylated residue in that peptide (IKGLVQPTRLL). This phosphorylation site was unexpected, as preliminary experiments demonstrated that free GST was not phosphorylated by GST-xPim-1 (data not shown). The identified autophosphorylation sites of xPim-1 are shown in Fig. 1 as boxed residues.

GST-xPim-1 was analyzed after extraction and purification from the bacteria without in vitro autophosphorylation. GST-xPim-1 was thrombinized to remove the GST, trypsinized, then the entire sample was loaded onto the IMAC column and analyzed by liquid phase chromatography mass spectrometry. Phosphopeptides containing the phosphorylated Ser-190 site (m/z 1213) as well as the dephosphorylated form (m/z 1133) were identified. This indicated that the GST-xPim-1 was already substantially autophosphorylated in the bacteria. The exact amount of phosphorylation by the time of purification could not be established as the liquid phase chromatography mass spectrometry treatment causes partial removal of the phosphate group, but more than 50% of GST-xPim-1 was estimated to be phosphorylated on Ser-190 (data not shown).

Site-directed Mutagenesis of xPim-1 Autophosphorylation Site and Analysis of Mutants

In vitro autophosphorylation experiments following phosphatase treatment were performed to determine if differences in phosphotransferase activity toward exogenous substrates existed between the dephosphorylated and autophosphorylated forms of GST-xPim-1. The phosphatases tested included broad specificity acid and alkaline phosphatases and a broad specificity, tyrosine-specific phosphatase corresponding to the intracellular domain of HPTPbeta (data not shown). However, the phosphotransferase activities of all samples of phosphatase-treated and autophosphorylated GST-xPim-1 toward the Pim-1 substrate peptide AKRRRLSA were similar. It was possible that the various phosphatases that were used may not have dephosphorylated residues that affected the phosphotransferase activity of Pim-1. In partial support of this, no band shifts in size of GST-xPim-1 were observed on an SDS-polyacrylamide gel after phosphatase treatment (data not shown).

To evaluate directly the importance of the major autophosphorylation site in xPim-1, PCR mutagenesis was used to construct two xPim-1 mutants by changing the Ser-190 residue to alanine (S190A) and to glutamic acid (S190E). Alanine, a nonphosphorylatable residue, mimicked the dephosphorylated state of the Pim-1, and glutamic acid, a charged acidic residue, was used in an attempt to imitate phosphorylation at this site. The mutants were expressed as bacterial fusion proteins, and products of the expected size were immunodetected with Xenopus Pim-1 antibodies by Western blotting analysis (Fig. 6A). An autoradiogram of in vitro autophosphorylated WT and mutant GST-xPim-1 species (Fig. 6B) demonstrated that the autophosphorylation of both mutants was reduced very significantly compared with the WT Pim-1. Although phosphoamino acid analysis was attempted repeatedly to determine if a proportional amount of phosphoserine was reduced compared with phosphothreonine, autophosphorylation of the mutants did not allow enough isotope to be incorporated into the protein to allow analysis by this method.


Fig. 6. Autophosphorylating activities of WT and S190 mutants of GST-xPim-1. GST-xPim-1 mutants S190A (lane 1) and S190E (lane 2) and wild-type (lane 3) were incubated in an autophosphorylation reaction with [gamma -32P]ATP and then subjected to SDS-polyacrylamide gel electrophoresis. Panel A, Western blotting with anti-xPim-1 antibody. Panel B, autoradiogram of Western blot shown in panel A with 64-h exposure. The migration positions of molecular mass marker proteins are indicated.
[View Larger Version of this Image (38K GIF file)]


The specific activity of WT GST-xPim-1 autophosphorylation was 107 pmol/min/mg, whereas the specific activities for autophosphorylation of the S190A and S190E mutants were estimated to be 4.9 and 5.2 pmol/min/mg, respectively. As the degree of autophosphorylation of the mutants was greatly reduced in these mutants, Ser-190 was confirmed as a major site of GST-xPim-1 autophosphorylation.

GST-xPim-1 Autophosphorylation at the Ser-190 Site Appears to Be Activating

To assess whether the exogenous phosphotransferase activities of the Ser-190 mutants were different from the WT GST-xPim-1, kinase assays were performed using the Pim-1 substrate peptide AKRRRLSA. To ensure that the effects observed did not reflect the bacterial expression system, the WT xPim-1 and S190E mutant were also expressed in COS cells. The Km and Vmax values of the mutants for AKRRRLSA peptide phosphorylation are shown in Table I. The apparent Km values were similar in the S190E and WT forms of GST-Pim-1, indicating that the replacement of a serine to a glutamic acid did not change the affinity of the enzyme for the substrate peptide. The Km value for the S190A mutant was lower than with the WT, indicating that this mutant had a higher affinity for the substrate peptide. However, the Vmax values for both S190A and S190E were similar and 7-fold lower than the Vmax value of the WT. Since Pim-1 is highly phosphorylated at Ser-190 in vivo, these findings indicated that phosphorylation at this site may activate Pim-1.

Table I.

Phosphotransferase activity of xPim-1 Ser-190 phosphorylation site mutants toward AKRRRLSA peptide

Values are the means of two separate experiments in which each assay was performed in triplicate.


E. coli expressed
COS cell expressed
Vmax Km Vmax Km

pmol · min-1 ·  mg-1 µM pmol · min-1 ·  mg-1 µM
Wild-type 124 35 3.5 35
S190A 17 5 NDa ND
S190E 16 42 0.4 7

a ND, not determined.


DISCUSSION

xPim-1 represents the first non-mammalian Pim-1 homolog to be characterized. In addition to high homology with the mammalian cognates, the full-length bacterially expressed frog GST-xPim-1 fusion protein was catalytically more active and was produced in much higher amounts with less degradation products than with human GST-Pim-1 constructs.3

The identification of the main sites of autophosphorylation of xPim-1 was complicated by the fact that the enzyme was substantially phosphorylated as it was obtained from the bacteria. However, IMAC-HPLC-ESI-MS permitted assignment of Ser-190 as a principal site of autophosphorylation in vivo. Site-directed mutagenesis confirmed these findings and indicated that phosphorylation of Ser-190 may serve to further activate the kinase. The introduction of a glutamic acid residue in place of Ser-190 was unable to mimic the effect of phosphorylation. It could be argued that a free hydroxyl group as in Ser-190 might be important for the catalytic activity of Pim-1. This might account for why the S190A and S190E mutants were 7-fold less active as kinases. However, in most GST-Pim-1 molecules from the bacteria, where the enzyme was highly active, it was already phosphorylated.

The other autophosphorylation sites of Pim-1 identified using IMAC-HPLC-ESI-MS analysis of tryptic phosphopeptides were Ser-4 and Thr-205. These phosphorylation sites are also conserved in all other known Pim-1 homologs, but it is unclear if phosphorylation of these sites has any physiological importance. In contrast to GST-xPim-1, the majority of autophosphorylation of human GST-Pim-1 is located on threonine residues by phosphoamino acid analysis, so it is possible that the Thr-205 site may be more important in the human enzyme (data not shown).

Both the Ser-190 and the Thr-205 residues are located within the "activation segment" of the kinase, so phosphorylation of these resides might be expected to induce conformational changes in the protein that may serve to modulate its kinase activity (for review, see Ref. 41). The Ser-190 site is easy to identify in other unrelated protein kinases, as it immediately follows the conserved DFG motif in catalytic subdomain VII (42). Sequence comparisons of catalytic domain VII indicate that in general, most other kinases contain hydrophobic methionine or leucine residues at this site. However, about 20 known kinases feature a serine residue at this location including ASFV, kinase from African swine fever virus (43); DM, myotonic dystrophy kinase (44); GSK3alpha /beta , rat glycogen synthase kinase-3 (45); sgg/zw3, kinase encoded by Drosophila segment polarity genes (46); MCK1, kinase encoded by a Saccharomyces cerevisiae meiotic induction gene (47); MDS1, a GSK3 homolog encoded by a S. cerevisiae gene that acts as a suppressor of mck1 mutants (48); ASKalpha /gamma , Arabidopsis thaliana GSK3 homologs (49); KNS1, a nonessential S. cerevisiae protein kinase (50); YAK1, a S. cerevisiae kinase downstream to the Ras/cAMP pathway (51); PST-K1, a distant relative of c-Mos (accession number L05668[GenBank]); Elm-1, a S. cerevisiae kinase involved in a differentiation pathway induced by nitrogen starvation (52); and Clk, a human kinase with homology to cdc2 (53). These kinases conserve the following (L/I/V/A)K(L/I/V)XDFGS(A/C) phosphorylation site motif, where X generally corresponds to a cysteine or isoleucine residue. This site has not previously been shown to be phosphorylated in protein kinases, and it represents a new location for regulation.

The Thr-205 site is a more familiar site of phosphorylation in protein kinases and is located seven residues upstream of the conserved APE motif in catalytic subdomain VIII. Other kinases that possess activating phosphorylation sites just before this location include cyclin-dependent kinases, mitogen-activated kinases, MAPKAPK-2, glycogen synthase kinase-3, Src, Rsk, and cAMP-dependent protein kinase (for review, see Ref. 54). Although many of these sites may be autophosphorylated, they are generally targeted by activating protein kinases that operate upstream in signaling pathways.

Although the immunodetection data and phosphoamino acid analysis indicated that GST-Pim-1 autophosphorylated on tyrosine residues, we were unable to identify unequivocally a tyrosine phosphorylation site by IMAC-HPLC-ESI-MS. The presence of tyrosine autophosphorylation sites was examined using the novel approach of identifying peaks that were shifted in mass and retention time after treatment with the tyrosine-specific phosphatase HPTPbeta . Although we were able to observe peptides that shifted in liquid phase chromatography mass spectrometry retention time after HPTPbeta treatment, these peptides were difficult to relate to the xPim-1. A tentative site, Tyr-133, was suggested by this method, but we did not confirm this result by site-directed mutagenesis as this residue was not well conserved in Pim-1 from other species.

The tyrosine at amino acid residue 198 in xPim-1 corresponded to Tyr-416 in Src, which is a conserved phosphorylation site in all tyrosine kinases (41, 55, 56) and led to the initial classification of Pim-1 as a tyrosine kinase (25, 56). In the search for tyrosine phosphorylation sites, this residue was not identified as being phosphorylated in GST-Pim-1. The lack of detectable autophosphorylation at Tyr-198 does not preclude the possibility that it may be subject to phosphorylation and regulation by other protein kinases.

It is very likely that phosphorylation is not the sole method of post-transcriptional regulation of Pim-1 function. Many other kinases in the cell are part of dynamic, multiprotein complexes. Pim-1 is a small 35-kDa protein that consists of a catalytic domain without obvious autoregulatory or association domains, but it may still complex with other proteins. An imperfect amphipathic alpha -helix motif in the COOH terminus of Pim-1, similar to that of cAMP-dependent protein kinase (57) and as of yet without a defined function, could be involved in regulatory protein-protein interactions. Alternatively, phosphorylation of Pim-1 at its NH2 terminus may also regulate the kinase indirectly. For example, autophosphorylation of the Mos oncogene-encoded serine/threonine protein kinase near its NH2 terminus at Ser-3 apparently stabilizes the kinase by preventing its ubiquitination and degradation (58, 59).


FOOTNOTES

*   This work was supported in part by grants from the National Cancer Institute of Canada (to S. L. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) L29495[GenBank].


§   Recipient of a Roman M. Babicki graduate fellowship and a National Science and Engineering Research Council of Canada studentship award. Present address: Dept. of Cellular and Molecular Pathology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
Dagger Dagger    Recipient of a Medical Research Council of Canada Scientist Award. To whom correspondence should be addressed: Kinetek Pharmaceuticals, Inc., Suite 150, 520 W. 6th Ave., Vancouver BC V5Z 1A1, Canada. Tel.: 604-876-5420 (ext. 129); Fax: 604-876-5498; E-mail: spelech{at}kinetekpharm.com.
1   The abbreviations used are: GM-CSF, granulocyte-macrophage colony-stimulating factor; G-CSF, granulocyte colony-stimulating factor; IL, interleukin; GST, glutathione S-transferase; IMAC, immobilized metal affinity chromatography; HPLC, high pressure liquid chromatography; ESI-MS, electrospray ionization-mass spectrometry; PCR, polymerase chain reaction; WT, wild-type, xPim-1, Xenopus Pim-1; MES, 4-morpholineethanesulfonic acid; MOPS, 4-morpholinepropanesulfonic acid.
2   C. K. Palaty, G. Kalmar, S. L. Pelech, and Ian Clark-Lewis, submitted for publication.
3   C. K. Palaty, G. Kalmar, G. Tai, S. Oh, L. Amankawa, M. Affolter, R. Aebersold, and S. L. Pelech, unpublished observations.

REFERENCES

  1. Berns, A., Selten, G., Cuypers, H. T., and Domen, J. (1988) in The Oncogene Handbook (Reddy, E. P., Shalka, A. M., and Curran, T., eds), pp. 121-134, Elsevier Science Publishers, Amsterdam
  2. Cuypers, H. T., Selten, G., Quint, W., Zijlstra, M., Maandag, E. R., Boelens, W., van Wezenbeek, P., Melief, C., and Berns, A. (1984) Cell 37, 141-150 [Medline] [Order article via Infotrieve]
  3. Selten, G., Cuypers, H. T., and Berns, A. (1985) EMBO J. 4, 1793-1798 [Abstract]
  4. van Lohuizen, M., Verbeek, S., Krimpenfort, P., Domen, J., Saris, C., Radaszkiewicz, T., and Berns, A. (1989) Cell 56, 673-682 [Medline] [Order article via Infotrieve]
  5. Möröy, T., Grzeschiczek, A., Petzold, S., and Hartmann, K.-U. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10734-10738 [Abstract]
  6. Verbeek, S., van Lohuizen, M., van der Valk, M., Domen, J., Kraal, G., and Berns, A. (1991) Mol. Cell. Biol. 11, 1176-1179 [Medline] [Order article via Infotrieve]
  7. Amson, R., Sigaux, F., Przedborski, S., Flandrin, G., Givol, D., and Telerman, A. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 8857-8861 [Abstract]
  8. von Lindern, M., van Agthoven, T., Hagemeijer, A., Adriaansen, H., and Grosveld, G. (1989) Oncogene 4, 75-79 [Medline] [Order article via Infotrieve]
  9. Meeker, T. C., Loeb, J., Ayres, M., and Sellers, W. (1990) Mol. Cell. Biol. 10, 1680-1688 [Medline] [Order article via Infotrieve]
  10. Sorrentino, V., McKinney, M. D., Giorgi, M., Geremia, R., and Fleissner, E. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 2191-2195 [Abstract]
  11. Wingett, D., Reeves, R., and Magnuson, N. S. (1992) Nucleic Acids Res. 20, 3183-3189 [Abstract]
  12. Wingett, D., Reeves, R., and Magnuson, N. S. (1991) J. Immunol. 147, 3653-3659 [Abstract/Free Full Text]
  13. Wingett, D., and Magnuson, N. S. (1995) J. Cell. Biochem. 19, (suppl.) 1-271
  14. Saris, C. J. M., Domen, J., and Berns, A. (1991) EMBO J. 10, 655-664 [Abstract]
  15. Saito, Y., Tada, H., Nazarea, M., and Honjo, T. (1992) Growth Factors 7, 297-303 [Medline] [Order article via Infotrieve]
  16. Domen, J., van der Lugt, N. M. T., Acton, D., Laird, P. W., Linders, K., and Berns, A. (1993) J. Exp. Med 178, 1665-1673 [Abstract]
  17. Domen, J., van der Lugt, N. M. T., Laird, P. W., Saris, C. J. M., Clarke, A. R., Hooper, M. L., and Berns, A. (1993) Blood 82, 1445-1452 [Abstract]
  18. Yip-Schneider, M. T., Horie, M., and Broxmeyer, H. E. (1995) Blood 12, 3494-3502
  19. Lilly, M., Le, T., Holland, P., and Hendrickson, S. L. (1992) Oncogene 7, 727-732 [Medline] [Order article via Infotrieve]
  20. Polotskaya, A., Zhao, Y., Lilly, M. L., and Kraft, A. S. (1993) Cell Growth & Differ. 4, 523-532 [Abstract]
  21. Quelle, F. W., Sato, N., Witthuhn, B. A., Inhorn, R. C., Eder, M., Miyajima, A., Griffin, J. D., and Ihle, H. N. (1994) Mol. Cell. Biol. 14, 4335-4341 [Abstract]
  22. Sato, N., Sakamaki, K., Terada, N., Arai, K., and Miyajima, A. (1993) EMBO J. 12, 4181-4189 [Abstract]
  23. Miura, O., Miura, Y., Nakamura, N., Quelle, F. W., Witthuhn, B. A., Ihle, J. N., and Aoki, N. (1994) Blood 84, 4135-4141 [Abstract/Free Full Text]
  24. Kinoshita, T., Yokota, T., Arai, K., and Miyajima, A. (1995) EMBO J. 14, 2266-2275
  25. Meeker, T. C., Nagarajan, L., ar-Rushdi, A., and Croce, C. M. (1987) J. Cell. Biochem. 35, 105-112 [Medline] [Order article via Infotrieve]
  26. Padma, R., and Nagarajan, L. (1991) Cancer Res. 51, 2486-2489 [Abstract]
  27. Friedmann, M., Nissen, M. S., Hoover, D. S., Reeves, R., and Magnuson, N. S. (1992) Arch. Biochem. Biophys. 298, 594-601 [Medline] [Order article via Infotrieve]
  28. Belle, R., Mulner-Lorillon, O., Marot, J., and Ozon, R. (1986) Cell Differ. 19, 253-261 [CrossRef][Medline] [Order article via Infotrieve]
  29. Zhang, S. C., and Masui, Y. (1992) J. Exp. Zool. 262, 317-329 [Medline] [Order article via Infotrieve]
  30. Maniatis, T., Fritsch, E. F., and Sambrook, J. (1982) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  31. Zakut-Houri, R., Hazum, S., Givol, D., and Telerman, A. (1987) Gene (Amst.) 54, 105-111 [Medline] [Order article via Infotrieve]
  32. Sanger, F., Coulson, A. R., Barrell, B. G., Smith, A. J. H., and Roe, B. A. (1980) J. Mol. Biol. 143, 161-178 [Medline] [Order article via Infotrieve]
  33. Sanghera, J., Peter, M., Nigg, E., and Pelech, S. L. (1992) Mol. Biol. Cell 3, 775-787 [Abstract]
  34. Hutner, W. B., and Greengard, P. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 5402-5406 [Abstract]
  35. Watts, J. D., Affolter, M., Krebs, D. L., Wange, R. L., Samelson, L. E., and Aebersold, R. (1994) J. Biol. Chem. 269, 29520-29529 [Abstract/Free Full Text]
  36. Domen, J., von Lindern, M., Hermans, A., Breuer, M., Grosveld, G., and Berns, A. (1987) Oncogene Res. 1, 103-112 [Medline] [Order article via Infotrieve]
  37. Hoover, D., Friedmann, M., Reeves, R., and Magnuson, N. S. (1991) J. Biol. Chem. 266, 14018-14023 [Abstract/Free Full Text]
  38. Craig, E. S., and Gross, C. A. (1991) Trends Biochem. Sci. 16, 135-140 [CrossRef][Medline] [Order article via Infotrieve]
  39. Leustek, T., Amir-Shapira, D., Toledo, H., Brot, N., and Weissbach, H. (1992) Cell. Mol. Biol. 38, 1-10 [Medline] [Order article via Infotrieve]
  40. Yu-Sherman, M., and Goldberg, A. L. (1992) EMBO J. 11, 71-77 [Abstract]
  41. Johnson, L. N., Noble, M. E. M., and Owen, D. J. (1996) Cell 85, 149-158 [Medline] [Order article via Infotrieve]
  42. Hanks, S. K., Quinn, A. M., and Hunter, T. (1988) Science 241, 42-52 [Medline] [Order article via Infotrieve]
  43. Baylis, S. A., Banham, A. H., Vydelingum, S., Dixon, L. K., and Smith, G. L. (1993) J. Virol. 67, 4549-4556 [Abstract]
  44. Brook, J. D., McCurrach, M. E., Harley, H. G., Buckler, A. J., Church, D., Aburatani, H., Hunter, K., Stanton, V. P., Thirion, J.-P., Hudson, T., Sohn, R., Zemelman, B., Snell, R. G., Rundle, S. A., Crow, S., Davies, J., Shelbourne, P., Buxton, J., Jones, C., Juvonen, V., Johnson, K., Harper, P. S., Shaw, D. J., and Housman, D. E. (1992) Cell 68, 799-808 [Medline] [Order article via Infotrieve]
  45. Woodgett, J. R. (1990) EMBO J. 9, 2431-2438 [Abstract]
  46. Siegfried, E., Perkins, L. A., Capaci, T. M., and Perrimon, N. (1990) Nature 345, 825-828 [CrossRef][Medline] [Order article via Infotrieve]
  47. Shero, J. H., and Hieter, P. (1991) Genes Dev. 5, 549-560 [Abstract]
  48. Puziss, J. W., Hardy, T. A., Johnson, R. B., Roach, P. J., and Hieter, P. (1994) Mol. Cell. Biol. 14, 831-839 [Abstract]
  49. Bianchi, M. W., Guivarc'h, D., Thomas, M., Woodgett, J. R., and Kreis, M. (1994) Mol. & Gen. Genet. 242, 337-345 [Medline] [Order article via Infotrieve]
  50. Padmanabha, R., Gehrung, S., and Snyder, M. (1991) Mol. & Gen. Genet. 229, 1-9 [Medline] [Order article via Infotrieve]
  51. Garret, S., and Broach, J. (1989) Genes Dev. 3, 1336-1348 [Abstract]
  52. Blacketer, M. J., Koehler, C. M., Coats, S. G., Myers, A. M., and Madaule, P. (1993) Mol. Cell. Biol. 13, 5567-5581 [Abstract]
  53. Johnson, K. W., and Smith, K. A. (1991) J. Biol. Chem. 266, 3402-3407 [Abstract/Free Full Text]
  54. Pelech, S. L., and Charest, D. L. (1995) in Progress in Cell Cycle Research (Meijer, L., Guidet, S., and Tung, L., eds), Vol. 1, pp. 33-52, Plenum Press, New York [Medline] [Order article via Infotrieve]
  55. Cooper, J. A., and MacAuley, A. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 4232-4236 [Abstract]
  56. Telerman, A., Amson, R., Zakut-Houri, R., and Givol, D. (1988) Mol. Cell. Biol. 8, 1498-1503 [Medline] [Order article via Infotrieve]
  57. Veron, M., Radzio-Andzelm, E., Tsigelny, I., and Taylor, S. (1994) Cell. Mol. Biol. 40, 587-596
  58. Nishizawa, M., Okazaki, K., Furuno, N., Watanabe, N., and Sagata, N. (1992) EMBO J. 11, 2433-2446 [Abstract]
  59. Freeman, R. S., Meyer, A. N., Li, J., and Donoghue, D. J. (1992) J. Cell Biol. 116, 725-735 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.